<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nitazoxanide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00507</strong>&#160; (APRD00558)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Nitazoxanide, also known by the brand name Alinia, is a synthetic nitrothiazolyl-salicylamide derivative and an anti-protozoal agent. It is approved for treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older. Following oral administration it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1&#8211;4 hours after administration. It is excreted in the urine, bile and feces. Untoward effects include abdominal pain, vomiting and diarrhea. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00507/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00507/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00507.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00507.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00507.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00507.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00507.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00507">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Adrovet</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Nitaxozanid</td><td>German</td><td>INN</td></tr><tr><td>Nitaxozanide</td><td>French</td><td>INN</td></tr><tr><td>Nitazoxanida</td><td>Spanish</td><td>INN</td></tr><tr><td>Nitazoxanidum</td><td>Latin</td><td>INN</td></tr><tr><td>Nodik</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Omniparax</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Alinia</td><td>Romark</td></tr><tr><td>Alpex Nizox</td><td>Alpex Pharmaceutical</td></tr><tr><td>ANNITA</td><td>Alpex Pharmaceutical</td></tr><tr><td>Azoxanid</td><td>G&amp;R</td></tr><tr><td>Celectan</td><td>Farma</td></tr><tr><td>Colufase</td><td>Roemmers</td></tr><tr><td>Coluquim</td><td>Quilab</td></tr><tr><td>Daxon</td><td>Siegfried</td></tr><tr><td>Dianide</td><td>General Pharma</td></tr><tr><td>Diar</td><td>ACI</td></tr><tr><td>Famidox</td><td>Lafrancol</td></tr><tr><td>Kaside</td><td>Lafrancol</td></tr><tr><td>Kazide</td><td>Lafrancol</td></tr><tr><td>Larvisol</td><td>Armofar</td></tr><tr><td>Lumbris</td><td>Farmedic</td></tr><tr><td>Mixel</td><td>California</td></tr><tr><td>Niazid</td><td>Apex</td></tr><tr><td>Nitax</td><td>Delta</td></tr><tr><td>Nitaxide</td><td>Beximco</td></tr><tr><td>Nitazet</td><td>Glenmark</td></tr><tr><td>Nitazofin</td><td>Bussi&#233;</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Armbid-NT</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Bacter-NZ</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Flagynor</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Inflobid-NXT</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Nitazet-O</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Nitzix-O</td><td>Nitazoxanide and Ofloxacin</td></tr><tr><td>Nizonide-O</td><td>Nitazoxanide and Ofloxacin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antiparasitic-agents">Antiparasitic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>55981-09-4</td></tr><tr><th>Weight</th><td>Average: 307.282<br>Monoisotopic: 307.026291103</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>YQNQNVDNTFHQSW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl acetate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C(S1)[N+]([O-])=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Phenol Esters</td></tr><tr><th>Direct parent</th><td>Phenol Esters</td></tr><tr><th>Alternative parents</th><td>Salicylamides; Benzamides; Benzoyl Derivatives; Nitrothiazoles; Phenol Ethers; 2,5-disubstituted Thiazoles; Alkyl Aryl Ethers; Aminothiazoles; Nitro Compounds; Secondary Carboxylic Acid Amides; Carboxylic Acid Esters; Nitronic Acids; Enolates; Organic Oxoazanium Compounds; Polyamines; Carboxylic Acids</td></tr><tr><th>Substituents</th><td>phenol ether; nitrothiazole; benzoyl; 2,5-disubstituted 1,3-thiazole; alkyl aryl ether; 1,3-thiazolamine; thiazole; azole; carboxamide group; nitro compound; nitronic acid; secondary carboxylic acid amide; carboxylic acid ester; polyamine; organic oxoazanium; ether; carboxylic acid; enolate; carboxylic acid derivative; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenol esters. These are aromatic compounds containing a benzene ring substituted by an hydroxyl group and an ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of diarrhea in adults and children caused by the protozoa <i>Giardia lamblia</i> and for the treatment of diarrhea in children caused by the protozoa <i>Cryptosporidium parvum</i>.</td></tr><tr><th>Pharmacodynamics</th><td>Nitazoxanide is an antifolate containing the pyrrolopyrimidine-based nucleus that exerts its antineoplastic activity by disrupting folate-dependent metabolic processes essential for cell replication. In vitro studies have shown that nitazoxanide inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), all folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides. Nitazoxanide is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, nitazoxanide is converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT. Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.</td></tr><tr><th>Mechanism of action</th><td>The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from Giardia lamblia directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of Cryptosporidium parvum appears to be similar to that of Giardia lamblia. Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity.</td></tr><tr><th>Absorption</th><td>The relative bioavailability of the suspension compared to the tablet was 70%. When administered with food the AUC and C<sub>max</sub> increased by two-fold and 50%, respectively, for the tablet and 45 to 50% and &#8804; 10%, respectively, for the oral suspension.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>Very High (greater than 99%), bound to proteins. Binding is not affected by degree of renal impairment.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Rapidly hydrolyzed to an active metabolite, tizoxanide (desacetyl-nitazoxanide), followed by conjugation, primarily by glucuronidation to tizoxanide glucuronide.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Nitazoxanide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01012">Desacetyl-nitazoxanide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1035">Details</a></td></tr><tr><td>Nitazoxanide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01013">Tizoxanide glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1036">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Tizoxanide is excreted in the urine, bile and feces, and tizoxanide glucuronide is excreted in urine and bile. Approximately two-thirds of the oral dose of nitazoxanide is excreted in the feces and one-third in the urine.</td></tr><tr><th>Half life</th><td>3.5 hours in patients with normal renal function</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>In acute studies in rodents and dogs, the oral LD<sub>50</sub> was higher than 10,000 mg/kg. Single oral doses of up to 4000 mg nitazoxanide have been administered to healthy adult volunteers without significant adverse effects. </td></tr><tr><th>Affected organisms</th><td><ul><li>Protozoa</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.7175</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5571</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7978</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8874</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9836</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9228</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7438</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8431</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5596</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6339</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.6655</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9027</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6341</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.6669</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5635</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.8322
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7746
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Ready biodegradable 
        </td>
        <td>
            0.5458
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.7902 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9283
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9295
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Romark laboratories</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Industriale Chimica S.R.L.</li>
<li><a href="http://www.qualiphar.com">Laboratoria Qualiphar NV SA</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.romark.com">Romark Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Suspension</td><td>Oral</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td>Searched, but no interactions found.</td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>